4D Molecular Therapeutics... (FDMT)
4D Molecular Therapeutics Inc. (FDMT) Stock Price, Analysis & Data
| Bid | 8.83 |
| Market Cap | 673.43M |
| Revenue (ttm) | 92.01M |
| Net Income (ttm) | -179.18M |
| Beta | 2.69 |
| EPS (ttm) | -2.63 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.98 |
| P/B (ttm) | 1.65 |
| P/S (ttm) | 7.32 |
| Earnings Date | Nov 10, 2026 |
| Ask | 14.5 |
| Volume | 773,744 |
| Avg. Volume (20D) | 847,591 |
| Open | 11.60 |
| Previous Close | 11.65 |
| Day's Range | 11.26 - 12.35 |
| 52-Week Range | 5.97 - 14.00 |
| Analyst | Strong Buy |
| Price Target | 31 (154.31%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injec...
Financial Performance
In 2025, 4D Molecular Therapeutics's revenue was 85.21M, an increase of 230,194.59% compared to the previous year's 37K. Earnings were -140.11M, a decrease of -12.9%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for FDMT stock is "Strong Buy". The 12-month stock price forecast is 31, which is upside of 154.31% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
